Solid lipid nanoparticles with TPGS and brij 78: A Co-Delivery vehicle of curcumin and piperine for reversing P-Glycoprotein-Mediated multidrug resistance in vitro

Oncology Letters

Volumn 13, Issue 1, 2017, Pages 389-395

  Tang, Jingling ^a   Ji, Hongyu ^a   Ren, Jinmei ^a   Li, Mengting ^a   Zheng, Nannan ^a   Wu, Linhua ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Curcumin; Multidrug resistance; P glycoprotein; Piperine; Solid lipid nanoparticles

Indexed keywords

OCTAMER TRANSCRIPTION FACTOR 4; SMALL INTERFERING RNA;

ARTICLE; CELL INVASION ASSAY; CELL PROLIFERATION ASSAY; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; MTT ASSAY; OSTEOSARCOMA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSIENT TRANSFECTION; WESTERN BLOTTING;

EID: 85004025771     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2016.5421     Document Type: Article

References (32)

1. Fodale V, Pierobon M, Liotta L and Petricoin E: Mechanism of cell adaptation: When and how do cancer cells develop chemoresistance? Cancer J 17: 89-95, 2011.
2. Kathawala RJ, Gupta P, Ashby CR Jr and Chen ZS: The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade. Drug Resist Updat 18: 1-17, 2015.
3. Shapira A, Livney YD, Broxterman HJ and Assaraf YG: Nanomedicine for targeted cancer therapy: Towards the overcoming of drug resistance. Drug Resist Updat 14: 150-163, 2011.
4. Anand P, Kunnumakkara AB, Newman RA and Aggarwal BB: Bioavailability of curcumin: Problems and promises. Mol Pharm 4: 807-818, 2007.
5. Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, Bueso-Ramos CE and Price JE: Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res 11: 7490-7498, 2005.
6. Aggarwal BB: Nuclear factor-kappaB: The enemy within. Cancer Cell 6: 203-208, 2004.
7. Limtrakul P, Chearwae W, Shukla S, Phisalphong C and Ambudkar SV: Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. Mol Cell Biochem 296: 85-95, 2007.
8. Chearwae W, Wu CP, Chu HY, Lee TR, Ambudkar SV and Limtrakul P: Curcuminoids purified from turmeric powder modulate the function of human multidrug resistance protein 1 (ABCC1). Cancer Chemother Pharmacol 57: 376-388, 2006.
9. Ganta S and Amiji M: Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm 6: 928-939, 2009.
10. Romiti N, Tongiani R, Cervelli F and Chieli E: Effects of curcumin on P-glycoprotein in primary cultures of rat hepatocytes. Life Sci 62: 2349-2358, 1998.
11. Bisht S, Feldmann G, Soni S, Ravi R, Karikar C, Maitra A and Maitra A: Polymeric nanoparticle-encapsulated curcumin (‘nanocurcumin’): A novel strategy for human cancer therapy. J Nanobiotechnology 5: 3, 2007.
12. Maiti K, Mukherjee K, Gantait A, Saha BP and Mukherjee PK: Curcumin-phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in rats. Int J Pharm 330: 155-163, 2007.
13. Tiyaboonchai W, Tungpradit W and Plianbangchang P: Formulation and characterization of curcuminoids loaded solid lipid nanoparticles. Int J Pharm 337: 299-306, 2007.
14. Shaikh J, Ankola DD, Beniwal V, Singh D and Kumar MN: Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci 37: 223-230, 2009.
15. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R and Srinivas PS: Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 64: 353-356, 1998.
16. Bhardwaj RK, Glaeser H, Becquemont L, Klotz U, Gupta SK and Fromm MF: Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 302: 645-650, 2002.
17. Najar IA, Sachin BS, Sharma SC, Satti NK, Suri KA and Johri RK: Modulation of P-glycoprotein ATPase activity by some phytoconstituents. Phytother Res 24: 454-458, 2010.
18. Li S, Lei Y, Jia Y, Li N, Wink M and Ma Y: Piperine, a piperidine alkaloid from Piper nigrum re-sensitizes P-gp, MRP1 and BCRP dependent multidrug resistant cancer cells. Phytomedicine 19: 83-87, 2011.
19. Kabanov AV, Batrakova EV and Alakhov VY: An essential relationship between ATP depletion and chemosensitizing activity of Pluronic block copolymers. J Control Release 91: 75-83, 2003.
20. Batrakova EV, Li S, Brynskikh AM, Sharma AK, Li Y, Boska M, Gong N, Mosley RL, Alakhov VY, Gendelman HE and Kabanov AV: Effects of pluronic and doxorubicin on drug uptake, cellular metabolism, apoptosis and tumor inhibition in animal models of MDR cancers. J Control Release 143: 290-301, 2010.
21. Guo Y, Luo J, Tan S, Otieno BO and Zhang Z: The applications of Vitamin E TPGS in drug delivery. Eur J Pharm Sci 49: 175-186, 2013.
22. Dong X, Mattingly CA, Tseng MT, Cho MJ, Liu Y, Adams VR and Mumper RJ: Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. Cancer Res 69: 3918-3926, 2009.
23. Tang J, Wang Y, Wang D, Wang Y, Xu Z, Racette K and Liu F: Key structure of brij for overcoming multidrug resistance in cancer. Biomacromolecules 14: 424-430, 2013.
24. Patel BD, Modi RV, Thakkar NA, Patel AA and Thakkar PH: Development and characterization of solid lipid nanoparticles for enhancement of oral bioavailability of Raloxifene. J Pharm Bioallied Sci 4 (Suppl 1): S14-S16, 2012.
25. Loveless VS, Surdock CP and Bhattacharjee H: Evaluation of zeta-potential and particle size of technetium 99mTc-sulfur colloid subsequent to the addition of lidocaine and sodium bicarbonate. J Nucl Med Technol 38: 49-52, 2010.
26. Yusuf M, Khan RA, Khan M and Ahmed B: Plausible antioxidant biomechanics and anticonvulsant pharmacological activity of brain-targeted β-carotene nanoparticles. Int J Nanomedicine 7: 4311-4321, 2012.
27. Raghunand N, He X, Van Sluis R, Mahoney B, Baggett B, Taylor CW, Paine-Murrieta G, Roe D, Bhujwalla ZM and Gillies RJ: Enhancement of chemotherapy by manipulation of tumour pH. Br J Cancer 80: 1005-1011, 1999.
28. Singh DV, Godbole MM and Misra K: A plausible explanation for enhanced bioavailability of P-gp substrates in presence of piperine: Simulation for next generation of P-gp inhibitors. J Mol Model 19: 227-238, 2013.
29. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219-234, 2006.
30. Eytan GD, Regev R, Oren G, Hurwitz CD and Assaraf YG: Efficiency of P-glycoprotein-mediated exclusion of rhodamine dyes from multidrug-resistant cells is determined by their passive transmembrane movement rate. Eur J Biochem 248: 104-112, 1997.
31. Tang J, Wang Y, Wang D, Xu Z, Racette K and Liu F: Key structure of brij for overcoming multidrug resistance in cancer. Biomacromolecules 14: 424-430, 2013.
32. Tang J, Fu Q, Wang Y, Racette K, Wang D and Liu F: Vitamin E reverses multidrug resistance in vitro and in vivo. Cancer Lett 336: 149-157, 2013.